The Future of Laboratory-Developed Tests in Hemostasis Laboratories

Abstract

Laboratory-developed tests (LDTs) are widely used in clinical hemostasis laboratories. The extent to which LDTs are regulated varies greatly around the world, and proposed changes to regulations have raised concerns about the future of LDTs in clinical laboratories. It is increasingly difficult to justify the use of an LDT where a commercially available method with regulatory approval is available. Conversely, where there is no suitable test with regulatory approval and there is a compelling clinical need, using an LDT outweighs the risk associated with not performing the test. We argue that LDTs are still required in specialist clinical laboratories to fulfill unmet clinical needs, and in lower middle-income countries where they are a vital resource.

Keywords

laboratory-developed tests - hemostasis - regulation

Publication History

Article published online:
05 January 2023

• References

• 1 Food and Drug Administration. Framework for Regulatory Oversight of Laboratory Developed Tests (LDTs) Draft Guidance for Industry, Food and Drug Administration Staff, and Clinical Laboratories. Accessed June 4, 2022 at: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/framework-regulatory-oversight-laboratory-developed-tests-ldts
• 2 Lichtenberg S, Trifonova OP, Maslov DL, Balashova EE, Lokhov PG. Metabolomic laboratory-developed tests: current status and perspectives. Metabolites 2021; 11 (07) 423
• 3 VALID Act of 2021. United States of America; 2021. Accessed December 20, 2022 at: https://www.congress.gov/bill/117th-congress/house-bill/4128/
• 4 Datema TAM, Roper KG, Cognat S. et al. Evaluation of the WHO laboratory quality stepwise implementation tool. Trop Med Int Health 2018; 23 (09) 943-949
• 5 Clinical Laboratory Improvement Amendments. State Operations Manual Appendix C - Survey Procedures and Interpretive Guidelines for Laboratories and Laboratory Services. Vol 3; 2017:5–21
• 6 International Organization for standardization. ISO 15189:2012 - Medical Laboratories-Requirements for quality and competence. Int Organ Stand ISO. 2012. Accessed December 20, 2022 at: https://www.iso.org/standard/56115.html
• 7 Favaloro EJ. Harmonising quality to the lowest clinical diagnostic standard? The case against regulation of in vitro diagnostics (IVDs) for use in clinical diagnostic laboratories. Aust J Med Sci 2010; 31 (02) 56-64
• 8 Food and Drug Administration/Center for Devices and Radiological Health. The Public Health Evidence for FDA Oversight of Laboratory Developed Tests: 20 Case Studies Office of Public Health Strategy and Analysis. FDA; 2015
• 9 Food and Drug Administration. Discussion Paper on Laboratory Developed Tests (LDTs). Accessed December 20, 2022 at: https://www.fda.gov/medical-devices/in-vitro-diagnostics/laboratory-developed-tests
• 10 US Government. 42 CFR 493.1253 - Standard: Establishment and Verification of Performance Specifications. United States; 2003. Accessed December 20, 2022 at: https://www.ecfr.gov/current/title-42
• 11 Food and Drug Administration. Template for Developers of Molecular Diagnostic Tests; 2021. Accessed December 20, 2022 at: https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/in-vitro-diagnostics-euas
• 12 Gardiner C, Coleman R, de Maat MPM. et al. International Council for Standardization in Haematology (ICSH) laboratory guidance for the verification of haemostasis analyser-reagent test systems. Part 2: Specialist tests and calibrated assays. Int J Lab Hematol 2021; 43 (05) 907-916
• 13 Gardiner C, Coleman R, de Maat MPM. et al. International Council for Standardization in Haematology (ICSH) laboratory guidance for the evaluation of haemostasis analyser-reagent test systems. Part 1: Instrument-specific issues and commonly used coagulation screening tests. Int J Lab Hematol 2021; 43 (02) 169-183
• 14 European Union. Directive 98/79/EC of the European Parliament and of the Council of 27 October 1998 on in Vitro Diagnostic Medical Devices; 1998. Accessed December 20, 2022 at: https://eur-lex.europa.eu/eli/dir/1998/79/oj
• 15 European Union. Regulation (EU) 2017/746 on In Vitro Diagnostic Medical Devices. European Union; 2017. Accessed December 20, 2022 at: http://data.europa.eu/eli/reg/2017/745/oj
• 16 Barberis M. In vitro diagnostic medical device regulation (IVDR): the end of laboratory developed tests (LDT)?. Pathologica 2021; 113 (02) 68-69
• 17 Bank PCD, Jacobs LHJ, van den Berg SAA. et al. The end of the laboratory developed test as we know it? Recommendations from a national multidisciplinary taskforce of laboratory specialists on the interpretation of the IVDR and its complications. Clin Chem Lab Med 2020; (November): cclm-2020-1384
• 18 European Commission. Questions and Answers: Stronger rules for placing medical tests on the market. Accessed December 20, 2022 at: https://ec.europa.eu/commission/presscorner/detail/en/QANDA_22_3289
• 19 National Association of Testing Authorities Australia (NATA). General Accreditation Guidance Estimating and Reporting Measurement Uncertainty of Chemical Test Results; 2018. Accessed December 20, 2022 at: https://www.nata.com.au/phocadownload/gen-accreditation-guidance/Estimating-and-reporting-measurement-uncertainty-of-chemical-test-results.pdf
• 20 Singapore Government. Health Products Act 2007; 2007. Accessed December 20, 2022 at: https://sso.agc.gov.sg/Act/HPA2007
• 21 Srivastava A, Santagostino E, Dougall A. et al. WFH guidelines for the management of hemophilia, 3rd edition. Haemophilia 2020; (26, Suppl 6): 1-158